StockData
VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Viking Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$25.05−0.12 (-0.48%)

Close on Oct 19, 2026

Market cap
$2.91B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Oct 21, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 29, 2026During market hours–$-1.10–
Q1 FY2026
Ended Mar 31, 2026
Apr 29, 2026During market hours–$-1.37–
Q4 FY2025
Ended Dec 31, 2025
Feb 11, 2026During market hours–$-1.38–
Q3 FY2025
Ended Sep 30, 2025
Oct 22, 2025During market hours–$-0.81–
Q2 FY2025
Ended Jun 30, 2025
Jul 23, 2025During market hours–$-0.58–
Q1 FY2025
Ended Mar 31, 2025
Apr 23, 2025During market hours–$-0.41–
Q4 FY2024
Ended Dec 31, 2024
Feb 5, 2025During market hours–$-0.32–
Q3 FY2024
Ended Sep 30, 2024
Oct 23, 2024During market hours–$-0.22–
Q2 FY2024
Ended Jun 30, 2024
Jul 24, 2024During market hours–$-0.20–
Q1 FY2024
Ended Mar 31, 2024
Apr 24, 2024During market hours–$-0.26–
Q4 FY2023
Ended Dec 31, 2023
Feb 7, 2024During market hours–$-0.25–

Press releases

Announcements Viking Therapeutics filed with the SEC